Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma

被引:57
作者
Kim, Hee Nam [1 ]
Lee, Il-Kwon [1 ]
Kim, Yeo-Kyeong [2 ]
Tran, Huong Thi Thanh [1 ]
Yang, Deok-Hwan [2 ]
Lee, Je-Jung [2 ]
Ho-Shin, Min
Park, Kyeong-Soo [3 ]
Shin, Myung-Geun [4 ]
Choi, Jin-Su
Kim, Hyeoung-Joon [1 ,2 ]
机构
[1] Chonnam Natl Univ, Genomr Res Ctr Hematopoiet, Hosp Hwasun, Kwangju 519809, South Korea
[2] Chonnam Natl Univ, Dept Hematol Oncol, Hosp Hwasun, Kwangju, South Korea
[3] Seonam Univ, Coll Med, Dept Prevent Med, Namwon, South Korea
[4] Chonnam Natl Univ, Hwasun Hosp, Dept Lab Med, Hwasun, South Korea
关键词
non-Hodgkin lymphoma; methylenetetrahydrofolate reductase; methionine synthase reductase; thymidylate synthase; polymorphism;
D O I
10.1111/j.1365-2141.2007.06893.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymorphisms in the genes coding folate-metabolizing enzymes affect the risk of some forms of cancer. We investigated the association between these polymorphisms and non-Hodgkin lymphoma (NHL) risk in a population-based study (583 cases and 1700 controls). The MTHFR 677TT and CT genotypes were associated with reduced risk for NHL [odds ratios (OR) = 0.79; 95% confidence intervals (CI) = 0.65-0.98 for 677CT and 0.61; 0.45-0.82 for 677TT] and diffuse large B-cell lymphoma (DLBCL) (OR = 0.68; 0.51-0.88 for 677CT; OR = 0.56; 0.38-0.83 for 677TT). The MTHFR 1298CC genotype was associated with increased risk for NHL (OR = 1.71; 1.07-2.75) and T-cell lymphoma (OR = 3.05; 1.53-6.11). The MTRR 66GG genotype was associated with increased risk for DLBCL (OR = 1.56; 1.03-2.38) and the TYMS 2R2R genotype was associated with increased risk for T-cell lymphoma (OR = 2.83; 1.33-6.01). Using subjects with 3RG3RG as a reference group, TYMS 2R2R was associated with increased risk for T-cell lymphoma (OR = 2.46; 1.04-5.79). Interestingly, we observed a reduced association between the TYMS 2R3RG genotype and DLBCL (OR = 0.61; 0.38-0.99). These results suggest that MTHFR, MTRR and TYMS polymorphisms may play a significant role in the risk for NHL.
引用
收藏
页码:287 / 294
页数:8
相关论文
共 39 条
[1]   COBALAMIN-DEPENDENT METHIONINE SYNTHASE [J].
BANERJEE, RV ;
MATTHEWS, RG .
FASEB JOURNAL, 1990, 4 (05) :1450-1459
[2]  
Chen J, 1996, CANCER RES, V56, P4862
[3]   Natural antisense (rTSα) RNA induces site-specific cleavage of thymidylate synthase mRNA [J].
Chu, JX ;
Dolnick, BJ .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3) :183-193
[4]   Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility [J].
Esteller, M ;
Garcia, A ;
Martinez-Palones, JM ;
Xercavins, J ;
Reventos, J .
CARCINOGENESIS, 1997, 18 (12) :2307-2311
[5]   Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels [J].
Feix, A ;
Fritsche-Polanz, R ;
Kletzmayr, J ;
Vychytil, A ;
Hörl, WH ;
Sunder-Plassmann, G ;
Födinger, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) :956-964
[6]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[7]   The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations [J].
Gaughan, DJ ;
Kluijtmans, LAJ ;
Barbaux, S ;
McMaster, D ;
Young, IS ;
Yarnell, JWG ;
Evans, A ;
Whitehead, AS .
ATHEROSCLEROSIS, 2001, 157 (02) :451-456
[8]  
Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
[9]  
Hishida A, 2003, HAEMATOLOGICA, V88, P159
[10]  
HORI T, 1985, JPN J CANCER RES, V76, P977